Trevena, Inc. (NASDAQ: TRVN), a clinical-stage biopharmaceutical company and leader in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that Maxine Gowen, Ph.D., its president and chief executive officer, will present at the Canaccord Genuity 34th Annual Growth Conference on Thursday, August 14, 2014 at 1:30 p.m. EDT at The InterContinental in Boston.
Help employers find you! Check out all the jobs and post your resume.
